Close Menu

NEW YORK – Sumitomo Dainippon Pharma Oncology said on Friday that it has dosed the first patient with the combination of its AXL kinase inhibitor dubermatinib (TP-0903) and the chemotherapy decitabine in the Phase Ib/II Beat AML Master Clinical Trial.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.